Microcap Ledger Immucell Corp /de/ $ICCC
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Capital Market
- Sector
- In Vitro & In Vivo Diagnostic Substances
- Headquarters
- Portland, ME
- Fiscal year end
- December 31
- Shares outstanding
- 9,082,197 [10-Q 2026-08-13]
What the company doesAI summary of filing
ImmuCell Corporation is a revenue-generating animal-health biologics company that develops, manufactures, and commercializes products designed to improve the health and performance of newborn dairy and beef calves. The company's primary product, First Defense®, uses hyperimmunized bovine colostrum to provide antibodies against the principal causes of neonatal calf diarrhea, including E. coli, bovine coronavirus, and bovine rotavirus, and is available in multiple formats. The company generates revenue through sales to U.S. and Canadian dairy operations, calf ranches, and beef producers via its in-house sales team and distributor partnerships; product sales totaled $27.6 million in 2025 with a 41 percent gross margin. In December 2025, the company decided to focus exclusively on First Defense® and pause further investment in its Re-Tain® product development initiative. [10-K 2026-03-30]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | $17.54M | $3.78M | $6.59M | $8.86M | [10-Q 2026-08-13] |
| FY ended Dec 2025 | $27.64M | −$1.04M | $2.48M | $3.81M | [10-K 2026-03-30] |
| FY ended Dec 2024 | $26.49M | −$2.16M | $357.9K | $3.76M | [10-K 2025-03-28] |
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-10-30 | 8,911,589 | [10-Q 2024-11-13] |
| 2025-03-21 | 8,982,623 | [10-K 2025-03-28] |
| 2025-05-06 | 9,037,397 | [10-Q 2025-05-14] |
| 2025-08-07 | 9,045,851 | [10-Q 2025-08-14] |
| 2025-10-31 | 9,045,851 | [10-Q 2025-11-13] |
| 2026-03-24 | 9,046,799 | [10-K/A 2026-05-13] |
| 2026-05-01 | 9,046,799 | [10-Q 2026-05-14] |
| 2026-07-31 | 9,082,197 | [10-Q 2026-08-13] |
- Shelf registration
- S-3 filed 2024-04-01; declared effective 2024-04-09 [S-3 2024-04-01]
Listing status
Current status: No Form 8-K Item 3.01 (listing notice) filings in the last 24 months, as of 2026-10-11.
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-06-18 | Te Boekhorst Paul Francis Olivier | buy | 8,000 | $9.49 | [4 2026-06-22] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-08-13 | 10-Q | Quarterly report |
| 2026-08-13 | 8-K | Results of operations |
| 2026-07-09 | 8-K | Results of operations |
| 2026-06-17 | 8-K | Shareholder vote results |
| 2026-06-10 | 8-K | Regulation FD disclosure |
| 2026-05-14 | 8-K | Results of operations |
| 2026-05-14 | 10-Q | Quarterly report |
| 2026-05-13 | 10-K/A | Amended report |
| 2026-05-08 | 8-K | Material agreement entered |
| 2026-04-24 | DEF 14A | Proxy statement |
| 2026-04-14 | PRE 14A | Proxy statement |
| 2026-04-14 | 8-K | Director or officer change; Other events |
Alerts for $ICCC
Email me when Immucell Corp /de/ files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.